Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1’2025 or early ...

Because the aim of the experiment is to compare GST with a GST fusion protein, it is necessary to prepare enough precleared lysate for each reaction. Efficient mixing of reagents is the key to ...

Q3 2024 Earnings Call Transcript November 8, 2024 Y-mAbs Therapeutics, Inc. reports earnings inline with expectations.

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Q3 2024 Earnings Call Transcript November 8, 2024 Operator: Good morning and welcome to Ocugen’s Third Quarter 2024 Financial ...

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

Innovent said its intention was to demonstrate executives’ commitment to the overseas business, but the deal was dropped ...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regu ...